Orthofix International N.V. (NASDAQ:OFIX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Alexis V. Lukianov as a Director
On December 13, 2016, the Board of Directors (the “Board”) of Orthofix International N.V. (the “Company”), consistent with a recommendation made by the Board’s Nominating and Governance Committee, appointed Alexis V. Lukianov as a director, effective immediately. The Board has determined that Mr. Lukianov is an independent director under the listing rules of the Nasdaq Stock Market. There are no transactions involving Mr. Lukianov requiring disclosure under Item 404(a) of Regulation S-K. In connection with Mr. Lukianov’s appointment, the Board resolved to increase its size from nine to ten directors, effective immediately. The Board has not yet determined Mr. Lukianov’s potential appointment to any committees of the Board.
Mr. Lukianov will receive the Company’s standard annual fee of $60,000 for non-employee director service. He will also receive, as of December 13, 2016, options to acquire 30,000 shares of common stock (vesting in 1/4th increments on each of the first, second, third and fourth anniversary of grant) to the Company’s 2012 Long-Term Incentive Plan.
Item 7.01.Regulation FD Disclosure.
On December 13, 2016, the Company issued a press release regarding the appointment described above. That press release is furnished herewith as Exhibit 99.1.
The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits
99.1Press Release, dated December 13, 2016.
About Orthofix International N.V. (NASDAQ:OFIX)
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim. Its Biologic solutions products include AlloQuent Structural Allografts, Trinity ELITE, Trinity Evolution, VersaShield and Collage Synthetic Osteoconductive Scaffold. Its Extremity Fixation solutions include Fixator, TrueLok, TL-HEX TrueLok Hexapod System, PREFIX and PREFIX 2, Centronail Titanium Nailing System and Galaxy Fixation System. Its Spine Fixation solutions products include Ascent LE Posterior Occipital Cervico-Thoracic (POCT) System, ATHLET Vertebral Body Replacement (VBR) System, NGage Surgical Mesh System and PILLAR AL PEEK Partial VBR System. Orthofix International N.V. (NASDAQ:OFIX) Recent Trading Information
Orthofix International N.V. (NASDAQ:OFIX) closed its last trading session down -1.43 at 36.97 with 127,760 shares trading hands.
